TITLE

Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos?

AUTHOR(S)
G., ANA MARÍA RIVAS; CARDONA-CASTRO, NORA
PUB. DATE
January 2009
SOURCE
CES Medicina;2009, Vol. 23 Issue 1, p61
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The prevalence of invasive fungal infections has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. For many years, amphotericin B and flucytosine were the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal drugs has increased, providing new therapeutic options for these patients. The purpose of this article is to summarize the pharmacologic profile of traditional antifungal drugs (amphotericin, flucytosine, itraconazole, fluconazole) as well as the ones recently licensed: the new triazoles (voriconazole, posaconazole) and the echinocandins (caspofungin, micafungin, anidulafungin).
ACCESSION #
65919057

 

Related Articles

  • Pharmacological Properties of Antifungal Drugs with a Focus on Anidulafungin. Mazzei, Teresita; Novelli, Andrea // Drugs;2009 Supplement, Vol. 69, p79 

    Drug classes for the treatment of invasive fungal infections include the polyenes, the triazoles and the echinocandins. Older agents such as the commonly used amphotericin B have a number of limitations, including toxicity and requirements for monitoring during treatment. These limitations led...

  • Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies. Steinbach, William J. // Current Drug Targets - Infectious Disorders;Sep2005, Vol. 5 Issue 3, p203 

    The optimal therapy for invasive aspergillosis (IA) is unknown, and there is little agreement on the exact antifungal management of IA. The previously stagnant landscape of antifungal choices for IA is rapidly changing with newer antifungals and newer targets. While amphotericin B has...

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S. B.; Chapuis, F.; Decullier, E.; Revol, B. G. P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2006, Vol. 25 Issue 2, p138 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...

  • High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Lafaurie, M.; Lapalu, J.; Raffoux, E. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p150 

    In this study, the authors sought to determine the efficacy of antifungal agents for preventing breakthrough invasive aspergillosis (IA) in a cohort of patients with persistent fever and neutropenia who received empirical antifungal therapy. Caspofungin was the most prescribed antifungal agent,...

  • The new antifungals-- safe and effective. Gallagher, Jason C.; Kauffman, Carol A.; Perfect, John // Patient Care;Jun2005, Vol. 39 Issue 6, p41 

    Discusses the advantages and indications of several antifungal agents. Reasons that the increased incidence of fungal infections shows no sign of decline or leveling of; Alternatives to amphotericin B deoxycholate; Infections caused by fungi, eukaryotes that are more complex organisms than...

  • Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Wingard, John R. // Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS38 

    Persistent or recurrent unexplained fever in neutropenic patients receiving antibiotics can be caused by invasive fungal infections, which are often difficult to diagnose. Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency...

  • Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Denning, David W.; Drusano, George L. // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p673 

    The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmaco dynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine...

  • Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis. Reed, Caitlin; Bryant, Richard; Ibrahim, Ashraf S.; Edwards Jr., John; Filler, Scott G.; Goldberg, Robert; Spellberg, Brad // Clinical Infectious Diseases;8/1/2008, Vol. 47 Issue 3, p364 

    Background. It has been axiomatic that echinocandins (e.g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we recently began treating rhino-orbital-cerebral mucormycosis (ROCM) with combination polyene-caspofungin therapy. Methods. To determine the...

  • AN OVERVIEW OF AZOLE ANTIFUNGALS. Shivaji Gavarkar, Pratibha; Shivaji Adnaik, Rahul; Krishna Mohite, Shrinivas // International Journal of Pharmaceutical Sciences & Research;Nov2013, Vol. 4 Issue 11, p4083 

    Fungal infections in critically ill or immunosuppressed patients were increasing in incidence in the human population over the last 1-2 decades. There were few advances in antifungal therapy and, until recently, there were few choices from which to select a treatment for systemic mycoses....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics